Bios group holds 8.58% of Lantern Pharma shares
Lantern Pharma Inc. received an updated ownership filing showing a Bios-affiliated investment group holding a significant minority stake.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
SCHEDULE 13D/A
Lantern Pharma Inc. received an updated ownership filing showing a Bios-affiliated investment group holding a significant minority stake. Bios Capital Management, Bios Advisors GP, Cavu entities, several Bios funds and individuals Leslie W. Kreis and Aaron G.L. Fletcher may be deemed to beneficially own 960,026 common shares, representing 8.58% of the outstanding stock, all with shared voting and dispositive power and no sole voting authority. The percentages are based on 11,184,423 shares outstanding as disclosed in Lantern Pharma’s Form 10‑Q filed on November 5, 2025. This Amendment No. 5 updates prior ownership statements without describing new transactions in this excerpt.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Lantern Pharma (LTRN) does the Bios group report?
The Bios-affiliated group reports beneficial ownership of 960,026 Lantern Pharma common shares, or 8.58% of the class. This percentage is calculated using 11,184,423 shares outstanding, as disclosed in the company’s Form 10-Q filed on November 5, 2025.
Who are the main reporting persons in this Lantern Pharma (LTRN) ownership filing?
The filing lists multiple Bios-affiliated entities and individuals, including Bios Capital Management, Bios Equity Partners, Cavu Management, Cavu Advisors, various Bios funds, BP Directors, and individuals Leslie W. Kreis and Aaron G.L. Fletcher, all reporting shared beneficial ownership of Lantern Pharma common stock.
What voting and dispositive power does the Bios group report over Lantern Pharma (LTRN) shares?
Each reporting person discloses zero sole voting or dispositive power and shared voting and dispositive power over the same 960,026 shares. Control is exercised through general partner and manager roles across the Bios funds and related entities described in the ownership structure.
On what share count is the 8.58% Lantern Pharma (LTRN) ownership based?
The 8.58% ownership figure is based on 11,184,423 Lantern Pharma common shares outstanding. That outstanding share number comes from Lantern Pharma’s Form 10-Q, which the issuer filed with the Securities and Exchange Commission on November 5, 2025.
What is the date of the event triggering this Lantern Pharma (LTRN) ownership amendment?
The event requiring this amended ownership statement is dated February 20, 2026. This date appears on the cover page and indicates when the circumstances necessitating Amendment No. 5 to the existing Lantern Pharma beneficial ownership report occurred.
How is beneficial ownership of Lantern Pharma (LTRN) shares structured among the Bios funds?
Beneficial ownership is spread across several Bios funds, including Bios Fund I, Bios Fund I QP, Bios Fund II, Bios Fund II QP, Bios Fund II NT and BP Directors. Various general partners and management entities may be deemed to share voting and dispositive power over their combined holdings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
See more from StockTitan in Google Search and AI answers.
Adds StockTitan as a preferred source · opens Google
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 5)
|
Lantern Pharma Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
51654W101 (CUSIP Number) |
Bios Equity Partners, LP 1751 River Run, Suite 400 Fort Worth, TX, 76107 817-984-9197 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
02/20/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
Bios Fund I, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
287,619.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
2.57 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of shares of common stock, par value $0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I"). Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS EQUITY PARTNERS II, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
478,079.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.27 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 101,665 Shares directly held by Bios Fund II, (ii) 331,974 Shares directly held by Bios Fund II QP and (iii) 44,440 Shares directly held by Bios Fund II NT. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities. Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND I QP, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
168,235.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
1.5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP"). Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND II, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
101,665.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.91 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by Bios Fund II, LP ("Bios Fund II"). Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND II QP, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
331,974.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
2.97 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP"). Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS FUND II NT, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
44,440.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.4 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT"). Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BP DIRECTORS, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
26,093.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.23 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of Shares directly held by BP Directors, LP ("BP Directors"). Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS EQUITY PARTNERS, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
481,947.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.31 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists (i) 287,619 Shares directly held by Bios Fund I, (ii) 168,235 Shares directly held by Bios Fund I QP and (iii) 26,093 Shares directly held by BP Directors. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities. Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS CAPITAL MANAGEMENT, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
960,026.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.58 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 287,619 Shares directly held by Bios Fund I, (ii) 168,235 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 101,665 Shares directly held by Bios Fund II, (v) 331,974 Shares directly held by Bios Fund II QP and (vi) 44,440 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
BIOS ADVISORS GP, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
960,026.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.58 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 287,619 Shares directly held by Bios Fund I, (ii) 168,235 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 101,665 Shares directly held by Bios Fund II, (v) 331,974 Shares directly held by Bios Fund II QP and (vi) 44,440 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
CAVU MANAGEMENT, LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
960,026.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.58 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 287,619 Shares directly held by Bios Fund I, (ii) 168,235 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 101,665 Shares directly held by Bios Fund II, (v) 331,974 Shares directly held by Bios Fund II QP and (vi) 44,440 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
CAVU ADVISORS, LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
TEXAS
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
960,026.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.58 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 287,619 Shares directly held by Bios Fund I, (ii) 168,235 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 101,665 Shares directly held by Bios Fund II, (v) 331,974 Shares directly held by Bios Fund II QP and (vi) 44,440 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
LESLIE W. KREIS | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF, OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
960,026.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.58 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 287,619 Shares directly held by Bios Fund I, (ii) 168,235 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 101,665 Shares directly held by Bios Fund II, (v) 331,974 Shares directly held by Bios Fund II QP and (vi) 44,440 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| CUSIP No. | 51654W101 |
| 1 |
Name of reporting person
AARON G.L. FLETCHER | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF, OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
960,026.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
8.58 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN, OO |
Comment for Type of Reporting Person:
Shared voting and dispositive power consists of (i) 287,619 Shares directly held by Bios Fund I, (ii) 168,235 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 101,665 Shares directly held by Bios Fund II, (v) 331,974 Shares directly held by Bios Fund II QP and (vi) 44,440 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,184,423 outstanding Shares as reported in the Form 10-Q filed by the Issuer on November 5, 2025.
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
Lantern Pharma Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS,
TEXAS
, 75201. | |
Item 1 Comment:
This Amendment No. 5 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statement on Schedule 13D/A filed with the Commission on December 1, 2023 ("Amendment No. 2"), as further amended by the statement on Schedule 13D/A filed with the Commission on March 1, 2024 ("Amendment No. 3"), as further amended by the statement on Schedule 13D/A filed with the Commission on June 12, 2024 ("Amendment No.4" and, together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, and Amendment No. 3, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer"). | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. | |
| (b) | The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. | |
| (d) | Except as described in this Amendment No. 5, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D. | |
| (e) | Not applicable. | |
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 99.1: Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020). | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comments accompanying signature:
BIOS FUND II, LP By: Bios Equity Partners II, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS FUND II QP, LP By: Bios Equity Partners II, LP, itsgeneral partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP,LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND II NT, LPBy: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its generalpartner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorneyin-Fact BIOS INCYSUS CO-INVEST I, LP By: Bios Equity Partners II, LP, its general partnerBy: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its generalpartner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III, LP By: Bios EquityPartners III, LP, its general partner By: Bios Capital Management, LP, its general partner By:Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOSFUND III QP, LP By: Bios Equity Partners III, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS FUND III NT, LP By: Bios Equity Partners III, LP, itsgeneral partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP,LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS CLINICALOPPORTUNITY FUND, LP By: Bios Equity COF, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner BPDIRECTORS, LP By: Bios Equity Partners, LP, its general partner By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS II, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in Fact BIOS EQUITY PARTNERS III, LP By: Bios CapitalManagement, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ JohnFucci John Fucci Attorney-in-Fact BIOS EQUITY COF, LP By: Bios Capital Management, LP, itsgeneral partner By: Bios Advisors GP, LLC, its general partner CAVU MANAGEMENT, LP By:Cavu Advisors, LLC, its general partner By: /s/ John Fucci Attorney-in-Fact BIOS CAPITALMANAGEMENT, LP By: Bios Advisors GP, LLC its general partner By: /s/ John Fucci Attorney in-Fact |